On April 25, Hanyu Pharmaceutical expressed at Hutong Yi the progress of orders for GLP-1 API. Recently, Hanyu Pharmaceutical (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company, signed a "Product Supply Agreement" with DS3RX LLC.
According to the contract, the customer expects the total purchase amount from the Wuhan subsidiary to be approximately US$22.4 million-24 million (equivalent to approximately RMB 1blackgold2megaways.62 billion yuan to 174 million yuan, subject to the actual transaction)blackgold2megawaysGLP-1 API.
Hanyu Pharmaceutical said that as of the day before, the company had received orders for GLP-1 API from overseas customers in September 2023, equivalent to RMB 219 million, and has been shipping them one after another; in November 2023 and February 2024, it received orders from the same overseas customer for the export of liraglutide injectable preparations to the United States, with a total transaction amount equivalent to RMB 175 million, and enjoyed a profit share of the product. The promotion of international business will help enhance the company's international popularity, enhance market competitiveness, and promote the company's long-term development.